We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Treatment of Atrial Fibrillation with a Dual Defibrillator in Heart Failure Patients (TRADE HF): Protocol for a Randomized Clinical Trial
News

Treatment of Atrial Fibrillation with a Dual Defibrillator in Heart Failure Patients (TRADE HF): Protocol for a Randomized Clinical Trial

Treatment of Atrial Fibrillation with a Dual Defibrillator in Heart Failure Patients (TRADE HF): Protocol for a Randomized Clinical Trial
News

Treatment of Atrial Fibrillation with a Dual Defibrillator in Heart Failure Patients (TRADE HF): Protocol for a Randomized Clinical Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Treatment of Atrial Fibrillation with a Dual Defibrillator in Heart Failure Patients (TRADE HF): Protocol for a Randomized Clinical Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Methods

Recent implantable cardiac resynchronization (CRT) devices allow electrical therapies to treat AF automatically. TRADE-HF (trial registration: NCT00345592; www.clinicaltrials.gov) is a prospective, randomized, double arm study aimed at demonstrating the efficacy of an automatic, device-based therapy for treatment of atrial tachycardia and fibrillation(AT/AF) in patients indicated for CRT. The study compares automatic electrical therapy to a traditional more usual treatment of AT/AF: the goal is to demonstrate a reduction in a combined endpoint of unplanned hospitalizations for cardiac reasons, death from cardiovascular causes or permanent AF when using automatic atrial therapy as compared to the traditional approach involving hospitalization for symptoms and in-hospital treatment of AT/AF.

Discussion

CRT pacemaker with the additional ability to convert AF as well as ventricular arrhythmias may play a simultaneous role in rhythm control and HF treatment. The value of the systematic implantation of CRT ICDs with the capacity to deliver atrial therapy in HF patients at risk of AF has not yet been explored. The TRADE-HF study will assess in CRT patients whether a strategy based on automatic management of atrial arrhythmias might be a valuable option to reduce the number of hospital admission and to reduce the progression the arrhythmia to a permanent form. Trial registration: NCT00345592

The article is published online within the journal, Trials and is free to access.

Advertisement